"id","name","uuid:ID","text","description","instanceType","label"
"Objective_1","OBJ1","f22ccdca-f30c-45a8-88e6-577c6b68bcb7","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","Main objective","Objective",""
"Objective_2","OBJ2","a0dc3789-da4b-41da-aedd-63469053c8cf","To document the safety profile of the xanomeline TTS.","Safety","Objective",""
"Objective_3","OBJ3","aca6041f-422d-4a10-954a-d8b6ed7a3be1","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","Behaviour","Objective",""
"Objective_4","OBJ4","4ead38cc-7c34-4d19-963e-2cc66820dcc9","To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5).","","Objective",""
"Objective_5","OBJ5","ca5bc71d-299c-4968-a908-27cd2fdadc75","To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2).","","Objective",""
"Objective_6","OBJ6","77c80ca4-2e47-4546-bd3f-8f228af4bc63","To assess the treatment response as a function of Apo E genotype.","","Objective",""
